Fundamental Analysis of Axsome Therapeutics Inc - Growth / Value Index


AXSM - Valuation Highlights

Valuation Analysis

   Tremendous increasing in Book Value last 3 year
   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 3911.14 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -2808.66 -14.43 12.60 %
Price to Book 4182.45 18.08 -35.90 % 25.01
Price to Sales 3316.12 12.76 -79.34 %
Enterprise Value to EBITDA Multiple -10.90 -18.43 -11.08 %


AXSM - Profitability Highlights

Profitability Analysis

   Piotroski F Score - Stable Value of 4.0
   Tsr Profitability Index - Very Poor Score of 5.00
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -148.91 -125.27 26.66 % -47.46
Return On Asset -54.17 -40.67 27.96 % -12.53
Net Profit Margin -118.07 -88.41 76.36 % -91.14
Operating Profit Margin -116.55 -67.59 81.19 % -89.70
EBITDA Margin -124.36 -65.07 81.89 % -89.70


Highlights
Market Cap3609.68 M
Enterprise Value3402.82 M
Price/Book TTM4182.45
Outstanding Share47495.80 K
Float/ Outstanding Share74.55%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score4.00
Altman Z Score3.64
Sloan Ratio-0.160
Peter Lynch Fair Value0


AXSM - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   STRONG JUMP IN NET SALE : YoY growth
   Annual sales of the company is increased for three years in a row
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 11.36
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 251023 K 440.80 % 4.85 %
Gross Profit 226217 K 4673.29 % 7.09 %
EBITDA -312162.00 K 2.07 % 42.85 %
Net Profit -296377.00 K 27.84 % 30.71 %
EPS -0.0271 14.42 % NA


AXSM - Stability Highlights

Stability Analysis

   Altman Z Score of 3.29 suggests good Stability
   Tsr Stability Index - Very Poor Score of 14.06
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -28.34
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.939 8.66 % 1.25
Cash Ratio 2.78 33.72 %
Quick Ratio 3.52 40.95 % 3.09
Shareholders Equity 32.47 -1.77 %
Debt to EBITDA -1.02 -93.41 %


Historical Valuation Ratios of Axsome Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Axsome Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Axsome Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Axsome Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)